Companies House · 11685363

CELLTRION HEALTHCARE UNITED KINGDOM LIMITED

UK registered company, private limited company, incorporated 19 Nov 2018.

Active
50
Public contracts
0
Spend payments
Total spend

CELLTRION HEALTHCARE UNITED KINGDOM LIMITED is a UK company registered at Companies House under number 11685363. This page links its registry record to its activity in UK public procurement — the contracts it has been awarded and the transparency-spend payments recorded against it.

Companies House record

Company number
11685363
Status
Active
Company type
Private Limited Company
Incorporated
19 Nov 2018
Country of origin
United Kingdom
Registered office
THE CHARTER BUILDING, UXBRIDGE, UB8 1JG, ENGLAND
Nature of business (SIC)
46460 - Wholesale of pharmaceutical goods
Accounts category
FULL
View source on data.gov.uk

Public sector contracts

Contract awards linked to CELLTRION HEALTHCARE UNITED KINGDOM LIMITED.

ProcurementBuyerAwardedValue
NP49425 Generic and Biosimilar Transition MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP39724 Generic and Biosimilar Cancer MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP47924 Cytokine ModulatorsThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP47924 Cytokine ModulatorsThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Branded and Biosimilar OphthalmologyThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP49425 Generic and Biosimilar Transition MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP49425 Generic and Biosimilar Transition MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP49425 Generic and Biosimilar Transition MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP49425 Generic and Biosimilar Transition MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Invitation to offer for NHS London Branded Medicines - Tranche A and AnnualNHS England
NHS South of England Branded Medicines - Tranche B and AnnualNHS England
NHS South of England Branded Medicines - Tranche B and AnnualNHS England
NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.The NHS Commissioning Board (operating under the name of NHS England)
NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.The NHS Commissioning Board (operating under the name of NHS England)
NHS South of England Branded Medicines - Tranche A - September 2023NHS England
NHS Framework, North of England, Branded Medicines - Tranche A and Annual TrancheThe NHS Commissioning Board (operating under the name of NHS England)
NHS Framework for Midlands and East Branded Medicines - Tranche B and Annual TrancheNHS England
NHS Framework for Midlands and East Branded Medicines - Tranche B and Annual TrancheNHS England
NHS Framework for North of England Branded Medicines - Tranche A and Annual TrancheNHS England
National Framework Agreement for Adalimumab Injection 1 April 2023NHS England
NHS Branded Medicines Framework for North of England and Midlands and East of England - 1 March 2024NHS England
NHS Branded Medicines Framework for North of England and Midlands and East of England - 1 March 2024NHS England
NHS Branded Medicines Framework for North of England and Midlands and East of England - 1 March 2024NHS England
NHS National Framework for the supply of Ustekinumab - 1 September 2024NHS England
NHS National Framework for the supply of Ustekinumab - 1 September 2024NHS England
NHS London Branded Medicines - Tranche B - September 2023NHS England
NHS London Branded Medicines - Tranche B - September 2023NHS England
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025NHS England
NHS National Framework Agreement for OmalizumabNHS England
NHS National Framework for the supply of Tocilizumab InjectionNHS England
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024NHS England
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024NHS England
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024NHS England
Biologic and Biosimilar MedicineseTenderwales
Medicinal Products and Pharma Funded Homecare Services (5315742) - Pre - Market EngagementRegional Business Services Organisation Procurement and Logistics Service
Medicinal Products and Pharma Funded Homecare Services (5315742) - Pre - Market EngagementRegional Business Services Organisation Procurement and Logistics Service
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025NHS England
Medicinal Products and Pharma Funded Homecare ServicesProcurement and Logistics Service
Medicinal Products and Pharma Funded Homecare ServicesProcurement and Logistics Service
Medicinal Products and Pharma Funded Homecare ServicesProcurement and Logistics Service
NHS Framework Agreement, Branded Medicines for London and South of England and Bevacizumab for North of England and Midlands and EastNHS England
NHS Framework Agreement, Branded Medicines for London and South of England and Bevacizumab for North of England and Midlands and EastNHS England
NHS Framework Agreement, Branded Medicines for London and South of England and Bevacizumab for North of England and Midlands and EastNHS England
NHS Framework Agreement, Branded Medicines for London and South of England and Bevacizumab for North of England and Midlands and EastNHS England
NHS Framework for the Midlands and East, Branded Medicines – Tranche A and Annual TrancheThe NHS Commissioning Board (operating under the name of NHS England)
Invitation to offer for NHS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)The NHS Commissioning Board (operating under the name of NHS England)
Invitation to offer for NHS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)The NHS Commissioning Board (operating under the name of NHS England)
Cytokine ModulatorsThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Cytokine ModulatorsThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Generic and Biosimilar Cancer MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")

Supplier identities

How this company appears as a supplier across the data.

FAQs about CELLTRION HEALTHCARE UNITED KINGDOM LIMITED

Is CELLTRION HEALTHCARE UNITED KINGDOM LIMITED an active company?

CELLTRION HEALTHCARE UNITED KINGDOM LIMITED (company number 11685363) is recorded as "Active", incorporated on 19 Nov 2018.

What does CELLTRION HEALTHCARE UNITED KINGDOM LIMITED do?

Its Companies House nature-of-business (SIC) is: 46460 - Wholesale of pharmaceutical goods.

Has CELLTRION HEALTHCARE UNITED KINGDOM LIMITED won UK public-sector contracts?

Yes — 50 public-sector contract awards are linked to this company in our data.

Where is CELLTRION HEALTHCARE UNITED KINGDOM LIMITED based?

Its registered office is THE CHARTER BUILDING, UXBRIDGE, UB8 1JG, ENGLAND.

Understand any company's public-sector footprint

Enable links Companies House to live procurement and spend data — see contracts, buyers and payments for any UK supplier.

Get in touch with Enable